Abstract
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation affecting the colonic mucosa, that can extend to the whole large bowel. The severity of mucosal lesions directly reflects the disease activity and severity and may be prognostic for an aggressive behavior of the pathology. Remission, is usually defined as resolution of symptoms. Recently, mucosal healing (MH) has emerged as an important end point of any shortterm medical therapy for IBD. It may predict long-term remission and may impact on the natural history of the disease in Crohn's disease (CD), while data in UC patients are still limited.
This review of the literature is focused on the recent evidence on the impact of medications on MH in UC and on the impact of MH on the natural course of UC.
Keywords: Ulcerative Colitis, Inflammatory bowel disease, Mucosal healing, Colonoscopy, Medical therapy, MMX, 5-ASA
Current Drug Targets
Title: Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Volume: 12 Issue: 10
Author(s): Gionata Fiorino, Monica Cesarini, Amedeo Indriolo and Alberto Malesci
Affiliation:
Keywords: Ulcerative Colitis, Inflammatory bowel disease, Mucosal healing, Colonoscopy, Medical therapy, MMX, 5-ASA
Abstract: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation affecting the colonic mucosa, that can extend to the whole large bowel. The severity of mucosal lesions directly reflects the disease activity and severity and may be prognostic for an aggressive behavior of the pathology. Remission, is usually defined as resolution of symptoms. Recently, mucosal healing (MH) has emerged as an important end point of any shortterm medical therapy for IBD. It may predict long-term remission and may impact on the natural history of the disease in Crohn's disease (CD), while data in UC patients are still limited.
This review of the literature is focused on the recent evidence on the impact of medications on MH in UC and on the impact of MH on the natural course of UC.
Export Options
About this article
Cite this article as:
Fiorino Gionata, Cesarini Monica, Indriolo Amedeo and Malesci Alberto, Mucosal Healing in Ulcerative Colitis: Where do we Stand?, Current Drug Targets 2011; 12(10) . https://dx.doi.org/10.2174/138945011796818216
DOI https://dx.doi.org/10.2174/138945011796818216 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Induction of Apoptosis by Curcumin and Its Implications for Cancer Therapy
Current Cancer Drug Targets Application of the Shortest Path Algorithm for the Discovery of Breast Cancer-Related Genes
Current Bioinformatics Molecular and Metabolic Imaging of Hepatic Neuroendocrine Tumors Following Radioembolization with 90Y-microspheres
Current Medical Imaging Role of Dietary Fiber and Short-Chain Fatty Acids in the Colon
Current Pharmaceutical Design Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Recent Clinical Experience with Oncolytic Viruses
Current Pharmaceutical Biotechnology Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Current Cancer Therapy Reviews Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes
Current Drug Targets HOXB7 and Hsa-miR-222 as the Potential Therapeutic Candidates for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Medicinal Chemistry of Antiviral/Anticancer Prodrugs Subjected to Phosphate Conjugation
Mini-Reviews in Medicinal Chemistry Potential for Predicting Toxicity and Response of Fluoropyrimidines in Patients
Current Drug Targets Synergistic Interactions between GW8510 and Gemcitabine in an In Vitro Model of Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry A Meta-Analysis of Proteomic Blood Markers of Colorectal Cancer
Current Medicinal Chemistry Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations
Current Medicinal Chemistry Cell Proliferation and Cytotoxicity Assays
Current Pharmaceutical Biotechnology Procyanidin B2 3,3″-di-O-gallate Inhibits Endothelial Cells Growth and Motility by Targeting VEGFR2 and Integrin Signaling Pathways
Current Cancer Drug Targets MicroRNAs and Physical Activity
MicroRNA Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review
Current Pharmaceutical Biotechnology Statins and Type 2 Diabetes Mellitus: An Update After 1 Year
Current Pharmaceutical Design